230 related articles for article (PubMed ID: 17487399)
1. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.
Cash J; Korchnak A; Gorman J; Tandon Y; Fraizer G
Oncol Rep; 2007 Jun; 17(6):1413-9. PubMed ID: 17487399
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.
Graham K; Li W; Williams BR; Fraizer G
Gene Expr; 2006; 13(1):1-14. PubMed ID: 16572586
[TBL] [Abstract][Full Text] [Related]
4. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
5. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
7. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
Tesan T; Gustavsson H; Welén K; Damber JE
BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
[TBL] [Abstract][Full Text] [Related]
9. Analysis of WT1 target gene expression in stably transfected cell lines.
Thäte C; Englert C; Gessler M
Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
[TBL] [Abstract][Full Text] [Related]
10. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.
Hanson J; Gorman J; Reese J; Fraizer G
Front Biosci; 2007 Jan; 12():2279-90. PubMed ID: 17127464
[TBL] [Abstract][Full Text] [Related]
11. Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin.
Kawada M; Inoue H; Arakawa M; Takamoto K; Masuda T; Ikeda D
Cancer Sci; 2007 Mar; 98(3):350-6. PubMed ID: 17270024
[TBL] [Abstract][Full Text] [Related]
12. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.
Menendez D; Krysiak O; Inga A; Krysiak B; Resnick MA; Schönfelder G
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1406-11. PubMed ID: 16432214
[TBL] [Abstract][Full Text] [Related]
13. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
Steiner H; Berger AP; Godoy-Tundidor S; Bjartell A; Lilja H; Bartsch G; Hobisch A; Culig Z
Eur J Cancer; 2004 May; 40(7):1066-72. PubMed ID: 15093584
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Inoue S; Branch CD; Gallick GE; Chada S; Ramesh R
Mol Ther; 2005 Oct; 12(4):707-15. PubMed ID: 16054437
[TBL] [Abstract][Full Text] [Related]
15. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
Mehraein-Ghomi F; Lee E; Church DR; Thompson TA; Basu HS; Wilding G
Prostate; 2008 Jun; 68(9):924-34. PubMed ID: 18386285
[TBL] [Abstract][Full Text] [Related]
16. Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter.
Hossain A; Saunders GF
Biol Reprod; 2003 Dec; 69(6):1808-14. PubMed ID: 12855602
[TBL] [Abstract][Full Text] [Related]
17. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc.
Dadiani M; Seger D; Kreizman T; Badikhi D; Margalit R; Eilam R; Degani H
Endocr Relat Cancer; 2009 Sep; 16(3):819-34. PubMed ID: 19398483
[TBL] [Abstract][Full Text] [Related]
18. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
19. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
Nadiminty N; Dutt S; Tepper C; Gao AC
Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells.
Thomas MA; Hodgson MC; Loermans SD; Hooper J; Endersby R; Bentel JM
J Cell Biochem; 2006 Dec; 99(5):1409-19. PubMed ID: 16817226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
